Hikma Pharmaceuticals PLC
LSE:HIK
Hikma Pharmaceuticals PLC
LSE:HIK
Price:
1 994 GBX
0.66%
Market Closed
Updated:
May 12, 2024
Hikma Pharmaceuticals PLC
Cash from Financing Activities
|
Hikma Pharmaceuticals PLC
Cash from Financing Activities Peer Comparison
Comparables:
GSK
AZN
VRNA
INDV
DPH
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Financing Activities
-$337m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Financing Activities
-£6.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Financing Activities
-$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Financing Activities
$92.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Financing Activities
-$62m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Financing Activities
£316.5m
|
CAGR 3-Years
39%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is Hikma Pharmaceuticals PLC's Cash from Financing Activities?
Cash from Financing Activities
-337m
USD
-337m
USD
Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Cash from Financing Activities amounts to -337m USD.
What is Hikma Pharmaceuticals PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-4%
-4%
Over the last year, the Cash from Financing Activities growth was -481%. The average annual Cash from Financing Activities growth rates for Hikma Pharmaceuticals PLC have been -4% over the past three years , -4% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
